Logo image of ANGN

ANGION BIOMEDICA CORP (ANGN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:ANGN - US03476J1079 - Common Stock

1 USD
+0.02 (+2.04%)
Last: 6/1/2023, 8:00:00 PM
0.9437 USD
-0.06 (-5.63%)
After Hours: 6/1/2023, 8:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ANGN. ANGN was compared to 190 industry peers in the Pharmaceuticals industry. While ANGN has a great health rating, there are worries on its profitability. ANGN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year ANGN has reported negative net income.
  • ANGN had a negative operating cash flow in the past year.
ANGN Yearly Net Income VS EBIT VS OCF VS FCFANGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 -20M -40M -60M -80M

1.2 Ratios

  • The profitability ratios for ANGN are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ANGN Yearly ROA, ROE, ROICANGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 0 200 -200 400

1.3 Margins

  • Looking at the Gross Margin, with a value of 352.37%, ANGN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of ANGN has grown nicely.
  • ANGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 352.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5YN/A
ANGN Yearly Profit, Operating, Gross MarginsANGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K -2.5K

More info and screens

7

2. Health

2.1 Basic Checks

  • ANGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ANGN has more shares outstanding than it did 1 year ago.
  • Compared to 1 year ago, ANGN has a worse debt to assets ratio.
ANGN Yearly Shares OutstandingANGN Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 10M 20M 30M
ANGN Yearly Total Debt VS Total AssetsANGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 20M 40M 60M 80M

2.2 Solvency

  • ANGN has an Altman-Z score of -0.82. This is a bad value and indicates that ANGN is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -0.82, ANGN perfoms like the industry average, outperforming 53.24% of the companies in the same industry.
  • ANGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.82
ROIC/WACCN/A
WACC8.33%
ANGN Yearly LT Debt VS Equity VS FCFANGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 0 50M -50M

2.3 Liquidity

  • ANGN has a Current Ratio of 20.00. This indicates that ANGN is financially healthy and has no problem in meeting its short term obligations.
  • ANGN has a Current ratio of 20.00. This is amongst the best in the industry. ANGN outperforms 92.13% of its industry peers.
  • A Quick Ratio of 20.00 indicates that ANGN has no problem at all paying its short term obligations.
  • ANGN's Quick ratio of 20.00 is amongst the best of the industry. ANGN outperforms 92.13% of its industry peers.
Industry RankSector Rank
Current Ratio 20
Quick Ratio 20
ANGN Yearly Current Assets VS Current LiabilitesANGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

  • ANGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 38.28%, which is quite impressive.
  • Looking at the last year, ANGN shows a very negative growth in Revenue. The Revenue has decreased by -97.79% in the last year.
  • Measured over the past years, ANGN shows a quite strong growth in Revenue. The Revenue has been growing by 15.59% on average per year.
EPS 1Y (TTM)38.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%68.3%
Revenue 1Y (TTM)-97.79%
Revenue growth 3Y15.59%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • ANGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.22% yearly.
  • Based on estimates for the next years, ANGN will show a very negative growth in Revenue. The Revenue will decrease by -25.99% on average per year.
EPS Next Y34.37%
EPS Next 2Y25.74%
EPS Next 3Y18.22%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
ANGN Yearly Revenue VS EstimatesANGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 5M 10M 15M 20M 25M
ANGN Yearly EPS VS EstimatesANGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -1 -2 -3 -4 -5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ANGN. In the last year negative earnings were reported.
  • Also next year ANGN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANGN Price Earnings VS Forward Price EarningsANGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANGN Per share dataANGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • ANGN's earnings are expected to grow with 18.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.74%
EPS Next 3Y18.22%

More info and screens

0

5. Dividend

5.1 Amount

  • ANGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANGION BIOMEDICA CORP / ANGN FAQ

What is the fundamental rating for ANGN stock?

ChartMill assigns a fundamental rating of 3 / 10 to ANGN.


Can you provide the valuation status for ANGION BIOMEDICA CORP?

ChartMill assigns a valuation rating of 2 / 10 to ANGION BIOMEDICA CORP (ANGN). This can be considered as Overvalued.


How profitable is ANGION BIOMEDICA CORP (ANGN) stock?

ANGION BIOMEDICA CORP (ANGN) has a profitability rating of 1 / 10.


Can you provide the financial health for ANGN stock?

The financial health rating of ANGION BIOMEDICA CORP (ANGN) is 6 / 10.